Biotech CEOs Have Three Big Nightmares: Chinese Rivals, AI Hype, and Trump’s Drug Price Reversal
Despite a brutal financial stretch for many vaccine companies, executives at the BIO 2026 conference say they still see reasons for optimism, though they are wrestling with three major worries: competition from Chinese biotech firms, whether artificial intelligence can actually make money, and the staying power of Trump-era drug price policies [182106][182094].
Industry leaders gathered at the major industry event said Chinese biotech companies are growing fast and threatening U.S. dominance [182094]. Executives also questioned the profitability of AI tools, noting that many investments have yet to show clear returns [182094]. Meanwhile, they expressed doubt that the Trump administration’s moves to lower drug prices will last under a new president [182094].
The key message from attendees is resilience. While the market has been punishing, the long-term need for vaccines remains strong [182106]. Companies are focusing on innovation and new pipelines to weather the current storm [182106]. For now, the industry is bracing for more hardship, but not surrendering to it [182106].
The conference highlighted a sector struggling to balance innovation with political and market pressures [182094].